157 related articles for article (PubMed ID: 33206840)
1. RETREATMENT WITH SURFACTANT IN VERY LOW BIRTH WEIGHT PRETERM INFANTS: RISK PREDICTORS AND THEIR INFLUENCE ON NEONATAL OUTCOMES.
Ferri WAG; Silva ACD; Sacramento EMF; Calixto C; Aragon DC; Caldas JPS
Rev Paul Pediatr; 2020; 39():e2019360. PubMed ID: 33206840
[TBL] [Abstract][Full Text] [Related]
2. Three-year perinatal outcomes of less invasive beractant administration in preterm infants with respiratory distress syndrome.
Ramos-Navarro C; Sánchez-Luna M; Zeballos-Sarrato S; González-Pacheco N
J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2704-2710. PubMed ID: 30526187
[No Abstract] [Full Text] [Related]
3. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
4. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R
JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567
[TBL] [Abstract][Full Text] [Related]
5. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis.
Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y
Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823
[TBL] [Abstract][Full Text] [Related]
6. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial.
Gortner L; Bartmann P; Pohlandt F; Bernsau U; Porz F; Hellwege HH; Seitz RC; Hieronimi G; Bremer C; Jorch G
Pediatr Pulmonol; 1992 Sep; 14(1):4-9. PubMed ID: 1437342
[TBL] [Abstract][Full Text] [Related]
7. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data.
Kribs A; Härtel C; Kattner E; Vochem M; Küster H; Möller J; Müller D; Segerer H; Wieg C; Gebauer C; Nikischin W; Wense Av; Herting E; Roth B; Göpel W
Klin Padiatr; 2010; 222(1):13-7. PubMed ID: 20084586
[TBL] [Abstract][Full Text] [Related]
8. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
Bassler D
Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
[TBL] [Abstract][Full Text] [Related]
9. Early administration of the second surfactant dose in preterm infants with severe respiratory distress syndrome.
Köksal N; Akpinar R; Cetinkaya M
Turk J Pediatr; 2009; 51(6):556-64. PubMed ID: 20196389
[TBL] [Abstract][Full Text] [Related]
10. Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?
Tsakalidis C; Giougki E; Karagianni P; Dokos C; Rallis D; Nikolaidis N
Turk J Pediatr; 2012; 54(4):368-75. PubMed ID: 23692717
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
13. Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome.
Abdel-Latif ME; Osborn DA
Cochrane Database Syst Rev; 2012 Oct; 10():CD008310. PubMed ID: 23076945
[TBL] [Abstract][Full Text] [Related]
14. Underdosing of Surfactant for Preterm Babies with Respiratory Distress Syndrome in Clinical Practice: A Retrospective Cohort Study.
Boix H; Rite S; Arruza L; Fernandez C; Serrano I; Baquedano I; Sanchez A; Ferreira E; Fernandez P; Gonzalez R; Elorza MD
Am J Perinatol; 2019 Jul; 36(9):943-948. PubMed ID: 30414597
[TBL] [Abstract][Full Text] [Related]
15. High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome.
Kattwinkel J; Bloom BT; Delmore P; Glick C; Brown D; Lopez S; Willett L; Egan EA; Conaway M; Patrie J
Pediatrics; 2000 Aug; 106(2 Pt 1):282-8. PubMed ID: 10920152
[TBL] [Abstract][Full Text] [Related]
16. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
[TBL] [Abstract][Full Text] [Related]
18. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.
Stevens TP; Blennow M; Soll RF
Cochrane Database Syst Rev; 2002; (2):CD003063. PubMed ID: 12076469
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome.
Bloom BT; Kattwinkel J; Hall RT; Delmore PM; Egan EA; Trout JR; Malloy MH; Brown DR; Holzman IR; Coghill CH; Carlo WA; Pramanik AK; McCaffree MA; Toubas PL; Laudert S; Gratny LL; Weatherstone KB; Seguin JH; Willett LD; Gutcher GR; Mueller DH; Topper WH
Pediatrics; 1997 Jul; 100(1):31-8. PubMed ID: 9200357
[TBL] [Abstract][Full Text] [Related]
20. Surfactant Administration in Preterm Infants: Drug Development Opportunities.
Taylor G; Jackson W; Hornik CP; Koss A; Mantena S; Homsley K; Gattis B; Kudumu-Clavell M; Clark R; Smith PB; Laughon MM
J Pediatr; 2019 May; 208():163-168. PubMed ID: 30580975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
